Interestingly, smoking patients with NSCLC seemed to have better responses to anti-PD-1/PD-L1, anti-CTLA-4, and anti-MUC1 drugs compared with non-smokers, which might affect therapy selection for smokers with NSCLC (193). This evidence concerns the gene CD274 and non-small cell lung carcinoma.